Coverage complications are not unusual in the U.S. health care system. But the challenge is magnified for these obesity ...
This will be a “pivotal year,” one expert says, for GLP-1 drugs, which are massively disrupting the benefits landscape.
Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of obesity ...